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S U M M A R Y
Objectives: Immunoglobulin (Ig) deﬁciency is a well-known risk factor for Streptococcus pneumoniae or
Haemophilus inﬂuenzae infections and noteworthy invasive diseases. However, the proportion of these
deﬁciencies in cases of invasive disease is unknown. The objective of this study was to evaluate the rate
of Ig deﬁciency in cases of invasive disease.
Methods: A prospective study was conducted from January 2008 to October 2010 in two French
hospitals. Measurement of Ig levels was carried out in patients hospitalized for invasive diseases.
Results: A total of 119 patients were enrolled in the study, with nine cases of H. inﬂuenzae and 110 cases
of S. pneumoniae invasive disease. There were 18 cases of meningitis, 79 of invasive pneumonia, and 22
other invasive diseases. Forty-ﬁve patients (37.8%) had an Ig abnormality, 37 of whom had an Ig
deﬁciency (20 IgG <6 g/l, four isolated IgA <0.7 g/l, and 13 isolated IgM <0.5 g/l), while eight had an
elevated monoclonal paraprotein. Nineteen of these 45 patients had a clearly deﬁned Ig abnormality,
with ﬁve primary deﬁciencies (three common variable immunodeﬁciencies and two complete IgA
deﬁciencies) and 14 secondary deﬁciencies, mainly lymphoproliferative disorders. All these deﬁciencies
were either not known or not substituted.
Conclusions: Humoral deﬁciency is frequent in patients with S. pneumoniae or H. inﬂuenzae invasive
disease and Ig dosage should be proposed systematically after such infections.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Streptococcus pneumoniae and Haemophilus inﬂuenzae infections
are classically divided into noninvasive forms (sinusitis, acute
otitis media, and pneumonia) and invasive disease, i.e., infections
with isolation of the organism from a normally sterile site,
especially bacteremic pneumonia and meningitis.1 Invasive
diseases are less frequent than pneumonia, although their
mortality rates and sequelae are higher. In the USA, there were
43 500 cases of S. pneumoniae invasive disease and 5000* Corresponding author. Tel.: +33 89 12 49 04; fax: +33 89 12 46 91.
E-mail address: martin.martinot@ch-colmar.fr (M. Martinot).
1201-9712  2013 The Authors. Published by Elsevier Ltd on behalf of International So
http://dx.doi.org/10.1016/j.ijid.2013.10.020attributable deaths in 2009.1 In France, before the introduction
of the heptavalent vaccine, there were approximately 6700
pneumococcal invasive diseases each year, with an incidence rate
of 11.4/100 000 inhabitants, and meningitis accounted for about
10% of these invasive diseases.2 With the introduction of the
heptavalent pneumococcal vaccine and routine immunization for
H. inﬂuenzae, France, like other countries, experienced a decrease in
invasive diseases in children younger than 2 years of age, while the
incidence rates in older patients increased.2,3
The mortality rates and incidence of S. pneumoniae and H.
inﬂuenzae infections are related to bacterial virulence factors, the
serotypes of S. pneumoniae, and also, most importantly, to host
factors.4 Numerous co-morbidities such as chronic bronchitis,
heart disease, hypertension, diabetes mellitus, asthma, chronic
liver disease, chronic renal failure, autoimmune disease, extreme
age, malignancies, immunosuppression, and modiﬁable risk
factors such as regular cigarette smoking, alcohol consumption,ciety for Infectious Diseases. Open access under CC BY-NC-SA license.
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S. pneumoniae and H. inﬂuenzae invasive diseases.4–6 Immunosup-
pression, splenectomy, HIV infection, and particularly humoral or
combined immune deﬁciencies are also important risk factors.7,8
Recommendations vary according to the country, although
immunoglobulin (Ig) determination is advised as a ﬁrst-line test
to evaluate humoral deﬁciency in cases of meningitis9 or repeated
H. inﬂuenzae or S. pneumoniae infections.10 However, very few
studies have focused on the rates of this deﬁciency in cases of S.
pneumoniae and H. inﬂuenzae infection. In an earlier study in 1994,
Ekdahl et al. reported that Ig deﬁciency was frequently observed in
cases of pneumococcal bacteremia.11 In this study we examined Ig
levels in patients hospitalized for S. pneumoniae and H. inﬂuenzae
invasive diseases, with the aim of evaluating the rate of Ig
deﬁciency in cases of invasive disease.
2. Patients and methods
This prospective study was conducted at one general hospital
and one university hospital in Alsace in northeastern France:
Hoˆpital Civil de Colmar in Colmar and the Nouvel Hoˆpital Civil in
Strasbourg. Patients were enrolled into the study between
January 2008 and October 2010. The subjects were eligible if
they had S. pneumoniae or H. inﬂuenzae invasive disease, deﬁned
as isolation of S. pneumoniae or H. inﬂuenzae in blood cultures,
cerebrospinal ﬂuid, a deep abscess, or normally sterile biological
ﬂuids (pleural, peritoneal, or synovial ﬂuid). In the case of
invasive disease, the practitioner in charge of the patient was
asked to measure the Ig levels (plasma protein electrophoresis
(PPE), IgG, IgA, and IgM). Patients without Ig determination were
excluded. The study was approved by the local ethics committee
(Strasbourg Ethics Committee ‘‘Comite´ de Protection des
Personnes EST IV’’).
After enrollment into the study, data were collected from the
patient’s medical records: age, gender, past medical history, reason
for hospitalization, date of microbiological specimen collection,
date of Ig determination, and outcome during hospitalization (fatal
or not). In cases with Ig abnormalities, no speciﬁc examinations
were scheduled, but an etiologic diagnosis after hospitalization
was sought from the patient’s medical records or after contact with
the practitioner in charge of the patient in order to diagnose a
primary or secondary humoral deﬁciency.12–15
2.1. Immunoglobulin analysis
We carried out PPE, IgG, IgM, and IgA assays, with IgG, IgA, and
IgM analyzed according to standard methods in the biochemistry
departments of the two hospitals. The nephelometric dosage assay
(international CRM 470) was used to measure Ig levels, while
either electrophoresis on agarose gels (Hyrasis, Sebia) or capillary
electrophoresis (Capillaries kit B1–B2+, Sebia) were used for PPE.
Immunoglobulin abnormalities were deﬁned either as a
measurable paraprotein peak or a low Ig level, deﬁned as follows
for adult patients >15 years of age: IgG <6 g/l, IgA <0.7 g/l, and IgM
<0.5 g/l. For children <15 years of age, the reference intervals were
those given by the manufacturer. Immunoglobulin values lower
than the thresholds were classiﬁed as zero for the calculations. In
cases of monoclonal gammopathy with a measurable paraprotein
peak, an estimation of residual functional gamma-globulin was
calculated using the PPE results by subtracting the value of the
measured peak from the value of total gamma-globulins.
2.2. Statistical analysis
Comparisons were performed using the Wilcoxon–Mann–
Whitney, Kruskal–Wallis, or Chi-square test, as appropriate.Differences were considered statistically signiﬁcant at p-values
0.05. The statistical analyses were performed using StatXact 9
(Cytel Studio, Cambridge, MA, USA).
3. Results
3.1. Demographic and clinical characteristics of the study population
A total of 279 patients were hospitalized for S. pneumoniae or H.
inﬂuenzae invasive disease between January 1, 2008 and October
31, 2010. One hundred and sixty of these patients were excluded
from the study because of an absence of Ig determination. The
remaining 119 patients were included in the study: 57 females and
62 males. The mean age of the patient cohort was 58.5 years; 10
children aged <15 years were included in the study.
The following classical risk factors were identiﬁed from the
patient records: HIV infection (n = 2), solid organ graft (n = 3),
chronic obstructive pulmonary disease (COPD; n = 12), asthma
(n = 7), cirrhosis (n = 7), diabetes (n = 18), solid tumors (n = 15),
renal insufﬁciency (n = 6), cardiac insufﬁciency (n = 5), ischemic
cardiopathy (n = 16), stroke (n = 5), smoking (n = 29, eight of whom
had quit), and alcoholism (n = 16, one of whom had stopped
drinking). Two cases of bacteremic pneumonia occurred during a
proven H1N1 inﬂuenza infection.
Nine patients had H. inﬂuenzae and 110 had S. pneumoniae
invasive disease. Eighteen patients had meningitis, 79 patients had
invasive pneumonia (74 cases of bacteremic pneumonia and ﬁve
cases of pneumonia with S. pneumoniae isolated from pleural ﬂuid),
and 22 patients had other invasive infections. Patients with
meningitis and other infections were younger than patients with
invasive pneumonia: mean age 45 and 52 years vs. 63 years,
respectively (p = 0.02).
Seventeen of the 119 patients (14.3%) with invasive disease
died; the highest mortality rate occurred in patients with
meningitis (33.3%), followed by patients with other invasive
diseases (22.7%) and then by invasive pneumonia (7.6%). The mean
age of adult patients who died was 70.3 years (range 30–95 years)
vs. 62.2 years (range 18–95 years) in adults with a favorable
outcome. No deaths occurred in the children. One patient with H.
inﬂuenzae invasive disease died, while 16 patients with S.
pneumoniae invasive disease died.
The characteristics of the 119 patients are summarized in
Table 1.
3.2. Immunoglobulin levels
Immunoglobulin levels (IgG, IgM, IgA, and PPE) were deter-
mined at a median of 4 days after bacteria isolation (range 0–214
days). Overall (adults and children) mean values were: IgG 11.27 g/
l (range 1.31–44 g/l), IgA 2.59 g/l (range 0–10.1 g/l), and IgM
0.96 g/l (range 0–5.93 g/l). Adult mean values were: IgG 11.32 g/l
(range 1.31–44 g/l), IgA 2.67 g/l (range 0–10.1 g/l), and IgM 0.96 g/l
(range 0–5.93 g/l) (Table 1).
Patients (both adults and children) with meningitis and other
infections had signiﬁcantly lower serum levels of IgG and IgA
than patients with invasive pneumonia: IgG 8.54 g/l and 9.3 g/l
vs. 12.43 g/l (p = 0.05), and IgA 1.37 g/l and 2.51 g/l vs. 2.88 g/l (p =
0.02), respectively. These lower levels did not reach statistical
signiﬁcance in the adult patients. The levels of IgM were similar in
the three groups. The data are summarized in Table 2 and
Figure 1.
Mean Ig levels in patients who died were 11.6 g/l for IgG, 2.58 g/
l for IgA, and 0.98 g/l for IgM, and were not statistically different
from levels in patients with a favorable outcome (11.4 g/l, 2.68 g/l,
and 0.95 g/l, respectively).
Table 1
Clinical data and immunoglobulin values (g/l) in patients with Streptococcus
pneumoniae or Haemophilus inﬂuenzae invasive disease
Total invasive disease (N = 119)
109 adults and 10 children
(age < 15 years)
Age, years, mean (range) 58.5 (5 months to 95 years)
Sex ratio 62 male/57 female
Type of infection, n (%)
Pneumonia 79 (66.4%)
Meningitis 18 (15.1%)
Other Infections 22 (18.5%)
Arthritis 2
Bacteremic otitis/sinusitis 3
Bacteremic endometritis 4
Primary peritonitis 2
Miscellaneousa 2
Primary bacteremia 9
Mortality rate, n (%) 17 (14.3%)
IgG, g/l, mean (range) 11.27 (1.31–44)
IgA, g/l, mean (range) 2.59 (0–10.1)
IgM, g/l, mean (range) 0.96 (0–5.93)
Immunoglobulin abnormalities, n (%) 45/119 (37.8%)
Low IgGb 20/119 (16.8%)
Isolated low IgAb 4/119 (3.4%)
Isolated low IgMb 13/119 (10.9%)
Quantiﬁed monoclonal gammopathy 8/119 (6.7%)
Deﬁned humoral deﬁciencies, n (%) 19/119 (16%)
Primary deﬁciencyc 5/119 (4.2%)
Secondary deﬁciencyd 14/119 (11.8%)
a One endocarditis and one vascular prosthesis infection.
b Low adult levels: IgG <6 g/l, IgA <0.7 g/l, IgM <0.5 g/l. Low values in children
are less than the reference intervals.
c Three cases of common variable immunodeﬁciency (CVID) and two cases of
complete IgA deﬁciency.
d Six cases of myeloma, two unexplored monoclonal gammopathy (MGUS), four
other lymphoproliferative disorders, one patient undergoing chemotherapy, and
one case of severe anorexia nervosa.
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Forty-ﬁve patients (37.8%) had an immunoglobulin abnormali-
ty; 37 had Ig deﬁciencies and eight had normal or elevated
immunoglobulin rates but with an elevated paraprotein level
(quantiﬁed monoclonal gammopathy peak). One 14-month-old
girl had an Ig deﬁciency that was an isolated partial IgA deﬁciency.
All other deﬁciencies occurred in adults: 20 of the 109 adults
(18.3%) had an IgG value <6 g/l, isolated or associated with a low
IgA or IgM; three (2.75%) had an isolated IgA value <0.7 g/l; and 13
(11.9%) had an isolated low IgM <0.5 g/l. Twenty-six Ig deﬁciencies
did not have a determined etiology. Only 19 patients had a clearly
deﬁned Ig abnormality: ﬁve cases of primary deﬁciency (three
cases of common variable immunodeﬁciency (CVID) and two
complete IgA deﬁciencies) and 14 cases of secondary deﬁciency
(six myeloma, two unexplored monoclonal gammopathy (MGUS),
four other lymphoproliferative disorders (chronic lymphocyticTable 2
Comparison of age and immunoglobulin levels in patients with Streptococcus pneumon
infectionsa
Meningitis (n = 18)
14 adults
4 children (age 1 month to 1 year)
Age, years 45 (5 m–89 y) 
IgG, g/l 8.54 (1.31–20.6) 
IgG, g/l, adults >15 years 9.58 (1.31–20.6) 
IgA, g/l 1.37 (0–3.57) 
IgA, g/l, adults >15 years 1.60 (0–3.57) 
IgM, g/l 0.86 (0–2.43) 
IgM, g/l, adults >15 years 0.85 (0–2.43) 
NS, not signiﬁcant.
a Results are given as the mean (range).leukemia/low-grade lymphoma), one patient undergoing chemo-
therapy, and one patient with severe anorexia nervosa). Of the 12
secondary hematological deﬁciencies, eight diseases were known
previously but had not been treated with Ig replacement, while
four diseases were discovered during the study. Of the two patients
with a secondary non-hematological deﬁciency, the causative
disease was known but not the humoral deﬁciency. For the eight
patients with normal or high Ig values and a gammopathy peak, the
gamma-globulin levels were either normal or elevated in relation
to the monoclonal Ig, although the estimated residual functional Ig
showed a pronounced gamma-globulin deﬁciency with a mean
residual total Ig functional level of 3.7 g/l (range 1.1–7.9 g/l). These
data are summarized in Table 1. A small number of patients had
experienced invasive disease before 2008 or recurrent infections
consistent with S. pneumoniae or H. inﬂuenzae infection (pneumo-
nia, sinusitis, or otitis). Of the 74 patients with normal Ig values,
three developed recurrent infections, while among the 45 patients
with abnormal Ig values, two had developed S. pneumoniae or H.
inﬂuenzae invasive disease previously (one CVID and one
idiopathic low IgG) and four patients had recurrent infections
(one CVID, two myeloma, and one idiopathic low IgM).
4. Discussion
Immunoglobulins play a crucial role during S. pneumoniae or H.
inﬂuenzae infection via opsonization or inhibition of toxins. An Ig
deﬁciency exposes patients to numerous infections, particularly
those caused by S. pneumoniae or H. inﬂuenzae,8 although there are
only limited data on the frequency of Ig deﬁciencies in S.
pneumoniae and H. inﬂuenzae invasive diseases. This study showed
a high rate of Ig abnormalities in patients with invasive S.
pneumoniae or H. inﬂuenzae infection hospitalized in the Colmar
and Strasbourg hospitals from January 2008 to October 2010.
4.1. Immunoglobulin levels according to invasive diseases and
outcome
Invasive diseases occurred mainly in adults (91.6%) and were
mostly due to S. pneumoniae (91.6%). Patients with meningitis or
other invasive diseases were younger and had lower IgG and IgA
levels than patients with invasive pneumonia. These lower Ig levels
may reﬂect the role played by Ig in meningitis and eventually other
invasive diseases; in cases with a low rate this may participate in
inadequate lowering of bacteremia or bacterial load, which
experimentally appears to correlate with meningitis.16 Mortality
in invasive disease patients in the present study was high (14.3%) and
similar to that reported by the US Centers for Disease Control and
Prevention (CDC) in 2010.1These ﬁndings reﬂect the severity of these
invasive diseases, with meningitis and other invasive diseases having
a higher mortality than invasive pneumonia. However, Ig levels did
not differ between survivors and non-survivors.iae or Haemophilus inﬂuenzae meningitis, invasive pneumonia, and other invasive
Pneumonia (n = 79)
74 adults
5 children (age 1–14 years)
Other (n = 22)
21 adults
1 child (age 7 years)
p-Value
63 (1–95 y) 52 (9 m–94 y) 0.02
12.43 (1.36–44) 9.30 (2.25–22.9) 0.05
12.31 (1.36–44) 9.45 (2.25–22.9) NS
2.88 (0–10.1) 2.51 (0–6.36) 0.02
2.88 (0–10.1) 2.60 (0–6.36) NS
0.97 (0–5.93) 1.01 (0–3.24) NS
0.96 (0–5.93) 1.02 (0–3.24) NS
Figure 1. Immunoglobulin values (IgG, IgA, and IgM; g/l) among patients with Streptococcus pneumoniae or Haemophilus inﬂuenzae meningitis (left box), other infections
(middle box), and invasive pneumonia (right box). Each box is bisected by a line representing the median value. The vertical lines (whiskers) represent the ranges of the
values. Whiskers extend to the most extreme values within 1.5 interquartile range (IQR). Mild outliers (within 3 IQR) are shown with points, and extreme outliers with
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We found a high rate of Ig abnormalities, with 45 of the 119
(37.8%) patients having an abnormal Ig and 20 of the 109 adult
patients having a low IgG level (18.3%). These proportions,
although high, are lower than those reported by Ekdahl et al.11
All but one of these deﬁciencies occurred in adults, although
squares.children were under-represented in our study, probably because of
vaccination protection in developed countries. The only deﬁciency
we observed in children was a partial IgA deﬁciency in a 1-year-old
girl with H. inﬂuenzae meningitis. However, it is probable that her
IgA level may subsequently have risen to a normal level.17 Of the 19
patients with a deﬁned etiology, there were only ﬁve cases of
primary deﬁciency, with three of these cases (2.52%) having CVID,
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population (1/3400 to 1/30 000). One patient was known to have
CVID but had no Ig replacement, while two were new cases
conﬁrmed by further investigations.12 Although we only selected
undetectable IgA as primary IgA deﬁciency, we diagnosed two
cases of complete IgA deﬁciency, that is 1.68% of the invasive
disease population in comparison to an expected IgA deﬁciency
rate of 1/333 to 1/2000.7,8,18 Similar to CVID, IgA deﬁciency is a
heterogeneous syndrome with some patients having no infection.
It is often recognized that other humoral deﬁciencies, such as IgG2
and IgG4 subclasses, or pneumococcal polysaccharide antibody
deﬁciency, combine with IgA deﬁciency to cause severe infections,
although these abnormalities are not systematically associat-
ed.18,19 We found a high level of selective IgM deﬁciency (13/109),
primarily in the oldest patients. A selective IgM deﬁciency is rare
and is deﬁned as a low IgM value with normal IgG and IgA levels.20
The literature describes IgM deﬁciency as a heterogeneous
disorder that may occur as a primary or secondary disorder (after
celiac disease for example) that can be asymptomatic or associated
with infections including those caused by encapsulated bacte-
ria.20,21
Twelve of the Ig abnormalities we observed were secondary to
lymphoproliferative diseases,13–15 mainly myeloma and chronic
lymphocytic leukemia. These diseases are known to increase the
risk of invasive disease, especially that caused by S. pneumoniae by
more than 35-fold.22 These lymphoproliferative disorders were
either not known (four cases) or did not receive Ig replacement.
4.3. Study limitations
Our study had several limitations that may have affected the
results and analysis. Firstly, there was only a small number of
children in the study and also a considerably lower number of H.
inﬂuenzae infections than pneumococcal infections. Secondly,
some data were only recorded in the medical charts as recurrent
infections, which may have led to an underestimation of their
actual rate. Thirdly, early and late determination of the Ig levels
may have affected the Ig values as discussed below. The cut-off
levels we used to deﬁne the Ig abnormality are a matter of debate.
No data exist to certify a threshold under which an infectious risk
exists. Therefore most authors have used laboratory values to
assess normality, with ‘abnormal’ values less than 6 g/l for IgG,
0.7 g/l for IgA, and 0.5 g/l for IgM. We used artiﬁcial cut-off levels
similar or lower to those provided by our laboratory or the
literature. Immunoglobulin determination is a simple and broadly
available test. The quality of the immune response as determined
by the pneumococcal polysaccharide antibody measurement
would be of interest to explore, as an adapted immune response
may compensate for an inadequate Ig level. However, these
techniques can be difﬁcult to perform and therefore are considered
as second-line tests for exploring humoral deﬁciencies.10 We did
not include IgG subclasses in our study as their interpretation and
management are difﬁcult and, similar to pneumococcal polysac-
charide antibody determination, are regarded as second-line
examinations.10 Half of the Ig measurements were carried out
within 4 days of invasive disease, although a few patients had
considerably later measurements (0–214 days) due to long
hospitalizations, with a change of ward allowing new Ig assays
when the data were missing. These late measurements, although
rare, were included in the statistical analyses. The infections may
have artiﬁcially modiﬁed IgG levels as a result of consumption or
hemodilutions caused by ﬂuid resuscitation. No recommendations
for Ig determination have been published and the results of
previous studies are confusing. Herer et al. found no variation in Ig
levels during community-acquired pneumonia at admission, at
recovery, or after discharge,23 although Ekdahl et al. found lowerIgG levels during acute infections.11 Another study performed by
Venet et al. during septic shock found lower IgG and IgM, but not
IgA levels during the ﬁrst 4 days, with normalization thereafter.24
In the present study, Ig deﬁciency was unknown or unexplained in
26 cases, and therefore a second analysis should always be
performed in such cases to conﬁrm the deﬁciency, as the infection
may have caused the lower Ig levels. The high rate of explained
abnormalities (19 primary or secondary deﬁciencies) conﬁrmed
the need for immediate Ig determination as a ﬁrst screening test to
detect humoral deﬁciencies.10 The precise timing of the Ig dosage
during hospitalization should be determined accurately (probably
after several days), but this was not within the scope of the current
study and therefore was not required. Immunoglobulin determi-
nation during acute infections allows prompt immunological
diagnosis and avoids losing patients to follow-up, although a
second Ig test should always be carried out at a later time.
4.4. Immunoglobulin deﬁciency treatment
Supportive care for patients with these humoral deﬁciencies is
based on vaccination against S. pneumoniae and H. inﬂuenzae, and
for certain patients Ig replacement and oral antibiotic therapy is
necessary. Vaccination is probably the simplest prevention, even
though its efﬁcacy is not guaranteed.8,25–27 The 13-valent
pneumococcal polysaccharide conjugate vaccine, followed by
the 23-valent vaccine is now recommended in non-immunized
immunocompromised patients.27 Immunoglobulin substitution is
indicated in primary hypogammaglobulinemia, using different
guidelines.28,29 Treatment of secondary hypogammaglobulinemia
mainly involves treating the underlying cause or discontinuing
medications that may result in hypogammaglobulinemia. Sup-
portive treatment in the form of replacement Ig and antibiotics
may be considered for hypogammaglobulinemia secondary to a
hematological malignancy (B-cell chronic lymphocytic leukemia,
non-Hodgkin lymphoma, multiple myeloma, and other B-cell
tumors).25,27–30 In secondary deﬁciency most recommendations
are for repeated infections, although it has been suggested that
patients with IgG levels <4 g/l should receive intravenous Ig
therapy.7 For myeloma, assessing humoral deﬁciency is problem-
atic because of pathologically high or normal Ig levels due to the
presence of paraprotein. However, in the present study, the
estimated residual Ig level was low, around 4 g/l. Immunoglobulin
replacement can be difﬁcult in cases of high paraprotein levels
with the associated risk of hypercoagulability due to hyperviscosi-
ty,31 and it is therefore necessary to consider Ig substitution during
the steady state.
5. Conclusions
Immunoglobulin determination during invasive disease
appears to improve the diagnosis of primary immunodeﬁciencies,
especially CVID, which are otherwise frequently diagnosed after
recurrent infections, with a delay of 6–8 years after the onset of the
ﬁrst characteristic symptoms.32 Immunoglobulin determination
during invasive disease also diagnoses a high rate of secondary
immunodeﬁciency, particularly hematological malignancies not
known or not adequately substituted. Measurement of immuno-
globulins during invasive diseases allows an early immunological
diagnosis and preventive therapy and is indicated as a ﬁrst-line
test to detect humoral deﬁciencies. Although this study did not
demonstrate a signiﬁcant improvement in the outcome of
infection, it is our view that patients with frequent and potentially
fatal infections of S. pneumoniae or H. inﬂuenzae invasive disease
should have Ig levels measured. This approach would allow the
diagnosis of most immunoglobulin abnormalities and therefore
allow implementation of preventive strategies when necessary.
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